US Broker Ratings

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 337% Potential Upside in the Biotechnology Arena

Relay Therapeutics, Inc. (NASDAQ: RLAY) has been a subject of interest within the biotechnology sector, offering a compelling narrative for investors seeking opportunities in precision medicine...

Claritev Corporation (CTEV) Stock Analysis: Navigating a 52-Week High Despite Financial Headwinds

Claritev Corporation (NASDAQ: CTEV) stands as a prominent player within the healthcare sector, specifically in the realm of health information services. With a market capitalization of..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 123% Potential Upside in the Biotech Sector

Emergent BioSolutions Inc. (NYSE: EBS) presents a compelling opportunity for investors seeking high-risk, high-reward plays in the healthcare sector. With a market capitalization of $328.38 million,..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A 266% Upside Potential in the Biotech Sector

Sana Biotechnology, Inc. (NASDAQ: SANA), a promising player in the biotech landscape, is capturing the attention of investors with a staggering potential upside of 266.01%. The..

Talkspace, Inc. (TALK) Stock Analysis: Exploring a 53.85% Potential Upside

Talkspace, Inc. (NASDAQ: TALK) is drawing considerable attention from investors, thanks to its solid potential upside of 53.85% as indicated by recent analyst ratings. This New..

Celcuity Inc. (CELC) Stock Analysis: Impressive 141.94% Potential Upside in Biotechnology Sector

Celcuity Inc. (NASDAQ: CELC), a notable player in the biotechnology sector, is capturing investor attention with a remarkable potential upside of 141.94%. This clinical-stage biotech firm,..

REGENXBIO Inc. (RGNX) Investor Outlook: Unveiling a 279.78% Potential Upside with Robust Revenue Growth

REGENXBIO Inc. (RGNX), a pioneer in gene therapy, is capturing the attention of investors with its impressive 279.78% potential upside, backed by substantial revenue growth. As..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech with a 145.91% Potential Upside

Investors with an interest in the biotechnology sector may want to pay close attention to Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a company with an ambitious portfolio..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: A 117% Potential Upside Awaits Investors

Investors seeking opportunities in the healthcare sector might find Organogenesis Holdings Inc. (NASDAQ: ORGO) to be an intriguing contender, particularly given its substantial potential upside. Specializing..

ATAI Life Sciences (ATAI) Stock Analysis: Exploring a 222% Potential Upside in the Biotech Arena

ATAI Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company headquartered in Berlin, Germany, is making waves in the biotechnology sector with a remarkable potential upside..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 54.78% Potential Upside Amidst Market Volatility

Myriad Genetics, Inc. (NASDAQ: MYGN) presents an intriguing investment opportunity within the healthcare sector, specifically the diagnostics and research industry. With a market capitalization of approximately..

Fulgent Genetics, Inc. (FLGT) Investor Outlook: Navigating Growth Potential Amidst a Challenging Market

Fulgent Genetics, Inc. (NASDAQ: FLGT) presents a compelling case for investors interested in the healthcare sector, specifically within the diagnostics and research industry. With a market..

Kamada Ltd. (KMDA): Investor Outlook with 117.55% Potential Upside

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, specifically within the drug manufacturing industry, is catching the eye of investors with an impressive..

Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 154.85% Potential Upside in the Biotech Sector

Verastem, Inc. (NASDAQ: VSTM) is capturing investor attention with its ambitious pipeline in the oncology space and a striking potential upside of 154.85%, according to the..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring 183.86% Upside Potential in the Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, is making waves in the healthcare sector with a focus on innovative solutions..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges and Opportunities in the Healthcare Sector

Avanos Medical, Inc. (NYSE: AVNS), a key player in the medical devices industry, is currently navigating a challenging landscape. With a market capitalization of $570.19 million,..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Biotech Player with 113.86% Potential Upside

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is attracting attention in the biotech sector with its promising pipeline of treatments for neurodegenerative diseases and endocrine conditions. Based in..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating a 44% Potential Upside Amid Revenue Challenges

Surmodics, Inc. (NASDAQ: SRDX), a prominent player in the healthcare sector specializing in medical devices, stands out in the marketplace with a distinct proposition. Based in..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unlocking a 39.83% Potential Upside

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is capturing investor attention with its significant potential upside of 39.83%. As a specialty pharmaceutical company focusing on pain management treatments,..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a 24% Potential Upside Amidst Biotechnology Challenges

For investors eyeing the biotechnology sector, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) presents a compelling, albeit challenging, proposition. With a market capitalization of $423.19 million, Ginkgo..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds